Please login to the form below

Not currently logged in
Email:
Password:

Merck gets US green light for allergy immunotherapy

Expected to provide a significant boost to company's partner Alk-Abello

US Food and Drug Administration (FDA)Merck & Co and Alk-Abello have been given the go-ahead by the US FDA to start selling their grass pollen allergy immunotherapy Grastek.

The US regulator approved Grastek for the treatment of Timothy grass pollen-induced allergic rhinitis with or without conjunctivitis. The product takes the form of an allergen extract given as a sublingual tablet that, over time, reduces the body's reaction to the allergen.

The approval was expected given that the FDA's Allergenic Products Advisory Committee voted unanimously to recommend its approval in December, although labelling for the new product will include a boxed warning detailing a link between the product and severe allergic reactions.

Grastek is the second allergy immunotherapy (AIT) product to be cleared for marketing in the US after Stallergenes' Oralair, which was approved last month. Merck was given the nod for the product in Canada earlier this year and it has been sold by Alk-Abello as Grazax in Europe since 2006.

Analysts are divided about the US commercial potential for Grastek, which is positioned as a patient-friendly alternative to current immunotherapeutic approaches which rely on a series of allergen injections. However, a number - including Jyske Bank - believe that sales of around $250m a year are possible, which would make it a minor product for Merck but a significant boost to Alk-Abello. 

"Every grass pollen season, many patients with moderate to severe allergic rhinitis experience nasal and ocular allergy symptoms at their worst while taking symptom-relieving medication," commented David Bernstein of the University of Cincinnati.

Patients often have multiple sensitivities and, while some may be candidates for immunotherapy, a portion decline allergy shots.

The FDA is also reviewing Merck and ALK-Abello's ragweed allergy Ragwitek, which was backed by the agency's advisory panel in January. A final decision on the ragweed product is expected mid-year.

Article by
Phil Taylor

15th April 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...
Precision medicine at Blue Latitude Health
At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and...
Understanding the evolving CAR-T market
In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in...

Infographics